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Abstract Farnesol strongly inhibited growth of a halophilic 
archaeon, Haloferax volcanii, with an IC5o value of only 2 pM 
(0.4 pg/ml) in rich medium and 50 nM (0.01 pg/ml) in minimal 
medium without lysis. Other isoprenoid alcohols such as isopen- 
tenol, dimethylallyl alcohol, geraniol, and geranylgeraniol at 500 
pM did not affect its growth. Mevalonate, which is the precursor 
of all isoprenoid membrane lipids in archaea, led to recovery of 
the growth inhibition of H. volcanii, but acetate had no such 
effect. Farnesol inhibited incorporation of acetate, but not me- 
valonate, into the lipid fraction. These results suggest hat farne- 
sol inhibited the biosynthetic pathway from acetate (acetyl-CoA) 
to mevalonate. Farnesol is known to be derived from the impor- 
tant intermediate of isoprenoids, farnesyl diphosphate (FPP), and 
found in neutral lipid fraction from this archaeon. Moreover, the 
cell-free extracts from H. volcanii could phosphorylate farnesol 
with ATP to generate farnesyl monophosphate and FPP. We 
conclude that farnesol-mediated isoprenoid synthesis regulation 
system by controlling farnesol concentration is present in H. 
volcanii. 
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1. Introduction 
Isoprenoid synthesis is known to be essential for diverse 
cellular functions. Some of the more important products of the 
pathway are sterols, ubiquinones, dolichols, carotenoids, pren- 
ylated proteins, and archaeal membrane lipids [14]. All mem- 
brane glycerolipids of archaea are isoprenoid ether lipids, in 
contrast o the fatty acid ester ones occurring in eubacteria and 
eukaryotes. Several isoprenoid biosynthetic enzymes of 
archaea have been studied: 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) reductase [5], geranytgeranyl diphosphate 
(GGPP) synthase [6-9], farnesylgeranyl diphosphate synthase 
[10], and geranylgeranylglyceryl phosphate synthase which syn- 
thesizes an ether linkage between glycerol and isoprenoid alco- 
hol [4]. On isoprenoid regulation in archaea, Cabrera et al. [11] 
reported the regulation of HMG-CoA reductase activity in 
response to mevalonate availability using mevinolin, a potent 
inhibitor of HMG-CoA reductase, in a halophilic archaeon. To 
our knowledge, there has been no other report concerning the 
regulation of archaeal isoprenoid synthesis. We have demon- 
strated that GGPP synthase purified from the methanogenic 
archaeon, Methanobacterium thermoJbrmicicum, synthesizes 
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Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; 
GGPP, geranylgeranyl diphosphate; FPP, farnesyl diphosphate. 
both farnesyl diphosphate (FPP) and GGPP in ratios depend- 
ent on certain conditions [6]. High GGPP concentration i hib- 
ited GGPP synthesis with GGPP synthase but not FPP synthe- 
sis. This led us to propose that GGPP synthase is one of the 
regulation points of isoprenoid synthesis in archaea [6,7]. Stud- 
ies on the regulation system of archaea re needed not only for 
understanding archaeal lipid biosynthesis but also for consider- 
ation as a new model of the early stage of cholesterogenesis, a  
Yamagishi [12] suggested that an enzyme involved in cholester- 
ogenesis of eukaryotes was derived from archaea. 
In this study, we demonstrate the evidence that farnesol- 
mediated isoprenoid synthesis regulation system by controlling 
farnesol concentration is present in H. volcanii. 
2. Materials and methods 
2.1. Chemicals 
Isopentenol, dimethylallyl alcohol, geraniol, farnesol, and ger- 
anylgeraniol were kind gifts from Kuraray. Squalene and DL-mevalo- 
hate were purchased from Sigma and Tokyo Kasei, respectively. 
[1-~4C]Acetate (2.09 MBq/mmol) and [1-3H]farnesol (2.1 MBq/mmol) 
were products of American Radiolabeled Chemicals. DL-[5-3H]mevalo - 
nate (1221 MBq/mmol) was a product of DuPont-NEN. 
2.2. Growth of H. volcanii 
The rich medium for H. volcanii IFO 14742 (=DSM 3757; strain 
DS-2) growth contained 5 g of yeast extracts, 4 g of KCI, 20 g of 
MgSO4.7HzO, 13 g of MgC12.6H20, 1 g of CaCI2"2H20, 0.2 g of 
NaHCO3, 1 g of glucose, and 206 g of NaC1 per liter, pH 7.0. The 
minimal medium, as described by Mevarech and Werczberger [13] with 
slight modifications, contained 206 g of NaCI, 36.9 g of MgSO4" 7H20, 
0.4 g of KC1, 0.3 g of NH4C1, 4.5 g of glycerol, 0.5 g of sodium succinate, 
0.5 g of CaC12.2H20, 0.2 g of KzHPO4, 1.6 mg of MnCI 2, 0.44 mg of 
ZnSO4, 2.3 mg of FeSO4, and 0.05 mg of CuSO4 per liter. The minimal 
medium was used only for determination f farnesol-induced growth 
inhibition, and the rich one for the other experiments. Isoprenoids and 
other compounds dissolved in ethanol were added to growth media at 
the same time of inoculation of H. volcanii. The final concentrations of 
ethanol were lower than 0.5%, which did not affect growth as deter- 
mined by A6~ omeasurement. 
2.3. Incorporation of lipid precursors into lipids with farnesol treatment 
At 2 h from addition of 0-20 ¢tM farnesol, the radioactive precursors 
of[114C]acetate (185 kBq) and [5-3H]mevalonate (185 kBq) were added 
to the H. volcanii cultures (10 ml). The cultures were incubated for 
3 h at 30°C with shaking. The cells were harvested by centrifugation 
and washed with basal salt buffer containing 20% NaC1, 2% MgCI2, 2% 
KCI, and 50 mM Tris (pH 7.0). Total lipids were extracted from the 
washed cells by the Brigh and Dyer method [14]. The total ipid fraction 
in chloroform solution was washed with 2 × 2 volumes of methanol/ 
water mixture (1:0.9), and then counted for radioactivity with a scintil- 
lation counter (Packard Tri-Carb 460). 
2.4. Farnesol phosphorylation assay 
Cell-free extracts of H. volcanii were prepared by sonication and 
centrifugation. Assay mixture contained 50 mM Tris-HC1 buffer (pH 
7.0), 6 mM MgCI2, 3.5 M KC1, 16 mM CHAPS, 10 mM ATP, 1 ,uM 
[3H]farnesol (37 kBq), and a suitable amount of the cell-free extracts 
in a final volume of 100/11. After incubation at 37°C for 1 h, the sample 
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was extracted with 1-butanol. The sample was separated by TLC 
(Merck, TLC aluminium sheet) with a solvent system of 1-propanol/ 
ammonia water/water (6: 3:1). The position of authentic standards, 
farnesyl monophosphate nd FPP, were visualized with iodine vapor. 
Iodine-positive spots on the TLC sheet were cut down and counted for 
radioactivity with a liquid scintillation counter (Packard Tri-Carb 460). 
3. Results and discussion 
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3.1. Growth inhibition of H. volcanii by Jarnesol and other 
isoprenoid alcohols 
Farnesol strongly inhibited the growth of the halophilic 
archaeon, H. volcanii, without lysis. The IC50 value of farnesol 
was only 2/tM (0.4 ktg/ml) in rich medium and 50 nM (0.01 
/zg/ml) in minimal medium (Fig. 1). Related isoprenoid alco- 
hols, geranylgeraniol (C20), geraniol (Ct0), dimethylallyl a cohol 
(C5), and isopentenol (Cs), did not inhibit growth at the concen- 
tration of 500/tM (Table 1). Bradfute and Simoni [15] reported 
that the farnesol derivative farnesyl acetate has the farnesol-like 
activity of accelerating HMG-CoA reductase degradation. Far- 
nesyl acetate was also tested against H. volcanii, but did not 
affect he growth at 100 gM (Table 1). This organism probably 
has little activity of hydrolyzing the ester linkage of farnesyl 
acetate to produce farnesol, and thus farnesyl acetate has no 
farnesol-like activity against his archaeon. 
3.2. Prevention of farnesol-induced growth inhibition by 
mevalonate 
Farnesol has been reported to accelerate HMG-CoA reduc- 
tase degradation i animal cells [16]. Early studies using radio- 
labeled and ~3C-labeled precursors howed that isoprenoids, 
polar lipids and squalene, in archaea [17-19] were synthesized 
from acetate and mevalonate aswell as cholesterol in eukaryo- 
tes. Inhibition ofHMG-CoA reductase r duces cholesterol syn- 
thesis in animal cells. Thus, in this archaeon, the isoprenoid 
precursors, mevalonate and acetate, were also expected to ex- 
press the recovery activity. Mevalonate at 5 mM partially pre- 
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Fig. 1. Farnesol-induced growth inhibition of H. volcanii. H. volcanii 
was grown in rich medium (D) and in minimal medium (I) with farnesol 
at the indicated concentrations. Growth was measured by A660 at 
2 days. Control culture had A66 o Of 0.8. 
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Fig. 2. Prevention of farnesol-induced growth inhibition of H. volcanii 
by mevalonate. H. volcanii was grown in rich medium containing farne- 
sol at 10 ,uM (o) and 20 ,uM (e) with the indicated concentrations of 
mevalonate. 
vented farnesol-induced growth inhibition (Fig. 2), while, ace- 
tate at 10 mM was not effective. 
3.3. Inhibition of incorporation oJ" [14C]acetate into lipids by 
jarnesol 
Farnesol effect on incorporation of isoprenoid precursors, 
[taC]acetate and [3H]mevalonate, was investigated. Untreated 
cells (control) synthesized lipids using [~4C]acetate and [3H]me- 
valonate (Fig. 3). Farnesol strongly inhibited incorporation of
[14C]acetate, but not [3H]mevalonate, into the lipid fraction 
(Fig. 3). Farnesol did not inhibit acetate incorporation i to 
trichloroacetic acid insoluble materials uch as protein (data 
not shown). These results suggest that the farnesol-inhibition 
point occurs early in the isoprenoid synthesis pathway prior to 
mevalonate synthesis from acetyl-CoA. Moreover, farnesol in- 
hibition of [~4C]acetate incorporation was more stronger than 
Table 1 
Effects of farnesol and related isoprenoid erivatives on growth of 
H. volcanii 
Isoprenoid Concentration Growth 
~M) (percent of control) 
None 100 
Isopentenol 100 101 
500 99 
Dimethylallyl a cohol 100 103 
500 98 
Geraniol 100 98 
500 97 
Farnesol 1 90 
5 15 
10 0 
Geranylgeraniol 100 108 
500 87 
Farnesyl acetate 50 102 
100 86 
H. volcanii was grown in rich medium for 2 days. 
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Fig. 3. Farnesol effect on incorporation of isoprenoid precursors. At 
2 h from farnesol addition at the indicated concentrations, the radioac- 
tive precursors [3H]mevalonate and [~4C]acetate w re added to 11. vol- 
canii cultures in rich medium. The cultures were incubated for 3 h, and 
total lipids were extracted and counted for their radioactivities. The 
sample not treated with farnesol had 2,630 dpm for 3H and 15,400 dpm 
for ~4C. Symbols indicate the following: (D), incorporation of [~4C]ace- 
tate; (t), incorporation of [3H]mevalonate; ( × ), dose-response curve 
for farnesol-induced growth inhibition obtained from Fig. 1. 
farnesol-induced growth inhibition, suggesting this is the pri- 
mary action point of farnesol. 
Edwards et al. [16,20] suggested that animal HMG-CoA re- 
ductase degradation occurs in the endoplasmic reticulum. The 
soluble HMG-CoA reductase of H. volcanii has significant ho- 
mology with the C-terminal half including active domain of 
HMG-CoA reductases of animals, but not with transmembrane 
domains at the N-terminal [5]. At least, farnesol did not inhibit 
HMG-CoA reductase activity of H. volcanii (data not shown). 
Halobacteria have been reported to synthesize HMG-CoA 
through unusual pathway using acetyl-CoA and lysine [18], 
though the pathway is not characterized. In H. volcanii, farne- 
sol might inhibit the pathway. Detailed farnesol inhibition 
mechanisms are now under investigation. 
3.4. Farnesol phosphorylation by cell-free extracts 
Evidence for farnesol phosphorylation has been obtained 
with algae [21]. Recently, in mammalian cells [22] and rat [23], 
farnesol has been reported to utilized for cholesterogenesis and 
protein isoprenylation, maybe after phosphorylation. Ther- 
moacidophilic archaeon, Sulfolobus acidocaldarius, possesses 
geranylgeraniol and farnesol phosphorylation enzymes (S. 
Ohnuma, personal communication). Cell-free extracts from 
Table 2 
Farnesol phosphorylation with cell-flee extracts from H. volcanii 
Substrate(s)* Product (dpm) 
Farnesyl monophosphate FPP 
[3H]Farnesol + ATP 2,340 1,530 
[3H]Farnesol 0 0 
*Concentrations were described in section 2. 
H. volcanii could also phosphorylate farnesol with ATP to pro- 
duce farnesyl monophosphate and FPP as shown in Table 2. 
In summary, in H. volcanii, farnesol inhibited early isopre- 
noid synthesis at a relatively low concentration. We and other 
investigators reported that archaea do not possess FPP syn- 
thase, and archaeal GGPP synthases synthesize both FPP and 
GGPP [(~9]. We demonstrated that using methanogen GGPP 
synthase, high concentration f GGPP inhibited GGPP synthe- 
sis, but not FPP synthesis [6]. If GGPP, a direct precursor of 
polar lipids, accumulates, it may cause FPP accumulation. Far- 
nesol derived from FPP must finally accumulate in the cells 
and/or the culture. It was reported that squalene synthase- 
deficient mutant [24] and squalene synthase inhibitor [25] 
caused farnesol accumulation i cells and/or culture fluid. Far- 
nesol is found in various archaea including H. volcanii. More- 
over, farnesol itself was phosphorylated to generate FPP. There- 
fore, farnesol concentration can be controlled by phosphoryla- 
tion and dephosphorylation by phosphatase. We propose that 
archaeal isoprenoid biosynthesis regulation by farnesol has fol- 
lowing scenario: GGPP accumulation -* FPP accumula- 
tion ~ farnesol production ~ reduction ofmevalonate synthe- 
sis from acetyl-CoA (or --~ farnesol phosphorylation). 
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